orchestrabiomed.com (OBIO): Market Cap to Revenue

Symbol and logo of brand Orchestra BioMed Inc. (OBIO)

Orchestra BioMed (OBIO) maintains a pristine image due to its alliances with medtech leaders to drive innovation. The business focuses on developing bioelectronic systems for the treatment of hypertension and cardiology. Currently, the company is deploying capital toward clinical trials and remains unprofitable. The price/sales ratio reflects the market valuation relative to revenue, with the current value standing at 12.20.

OBIO Orchestra BioMed Inc. P/S Multiple (04/28/2023 - 11/13/2026)

Analytical breakdowns for Orchestra BioMed (OBIO)

- share price and consensus valuation forecast:
Price Performance Chart Orchestra BioMed Inc.|OBIO - Price Target Chart
- stock exchange capitalization data:
Market Valuation Orchestra BioMed|OBIO - Enterprise Value
- book value of equity indicators:
Net Asset Value per Share Orchestra BioMed|OBIO - Book Capitalization|Capitalization to Book Value Ratio orchestrabiomed.com|OBIO - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Orchestra BioMed|OBIO - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio orchestrabiomed.com|OBIO - Company Aggregate Debts|Debts to Book Capitalization Orchestra BioMed|OBIO - Company Long-Term Debt|Company Short-Term Debt Orchestra BioMed|Intermediate Coverage Ratio orchestrabiomed.com
- earnings and multiples data:
OBIO - Net Profit|Expected Net Profit Orchestra BioMed|OBIO - Price to Earnings Ratio|Forward Price to Earnings Multiple Orchestra BioMed Inc.|OBIO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Orchestra BioMed|OBIO - Operating profit EBITDA|Net earnings per share for the last four quarters Orchestra BioMed|OBIO - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months orchestrabiomed.com|OBIO - Earnings per share growth in current year|Expected earnings per share growth for next year Orchestra BioMed
- issuer revenue and sales details:
OBIO - Revenue and Sales Volume|Company Expected Sales Volume orchestrabiomed.com|OBIO - Price-to-Revenue Ratio|Market Cap to Projected Revenue Orchestra BioMed
General company analysis:OBIO Orchestra BioMed Inc.
Core merchandise of Orchestra BioMed, Inc.

The selection of defensive assets is based on identifying undervalued companies with stable capital, which for Orchestra BioMed (OBIO) is confirmed by its status as a trusted partner for global medtech leaders in bringing innovations to market. An analysis of the historical P/S trend allows for the correlation of the business's market value with its actual revenue, determining the asset's degree of overheating and identifying the margin of safety through the ratio of market capitalization to sales volumes.

Competitors of Orchestra BioMed

BSX (bostonscientific.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Edwards Lifesciences Corporation EW|RMD - Market Cap to Revenue|OmniPod - P/S Multiple|Price to Sales Zimmer Biomet Holdings|COO: P/S Multiple|Market Cap to Revenue Ratio ALGN|GMED (Globus Medical) - P/S Multiple|TransMedics Group Inc (TMDX) - Price-to-Revenue Coefficient|P/S Multiple ATEC|Market Cap to Revenue Artivion Corp AORT|P/S Multiple ENOV (Enovis Corporation)|P/S Multiple integralife.com IART|ESTA - Price-to-Revenue Ratio|BBNX: Price-to-Revenue Ratio|IRMD (Iradimed) - Market Cap to Revenue|Embecta Health - Market Capitalization-to-Revenue Ratio|TNDM (Tandem Diabetes Care) - P/S Multiple|Price to Sales axogeninc.com AXGN|Price-to-Revenue Ratio SI-BONE (SIBN)|Orthofix Medical (OFIX) - Price-to-Revenue Multiple|Bioventus Corp - Market Cap to Revenue|P/S Multiple OrthoPediatrics Corp KIDS|Treace Medical Concepts - P/S Multiple|Price-to-Revenue Coefficient blade.com SRTA|Carlsmed (CARL) - Price-to-Revenue Ratio|Price-to-Sales Ratio RXST (RxSight Inc)|Price-to-Revenue Ratio ClearPoint Neuro Inc.|Market Cap to Revenue Stereotaxis Corporation (STXS)|P/S Multiple STIM|SGHT - Price to Sales|Price-to-Revenue Ratio Anika Therapeutics, Inc. ANIK|NSPR: Market Cap to Revenue Ratio|ZJYL: Market Cap to Revenue|Vivani Medical, Inc. - Market Cap to Sales Volume|xtantmedical.com (XTNT) - Price-to-Revenue Ratio|Price to Sales n1mtc.com (NMTC)|Price-to-Revenue Ratio Modular Medical Inc|MYO: Market Capitalization-to-Revenue Ratio|P/S Multiple COCH|Market Cap to Revenue Vivos Therapeutics Inc VVOS|P/S Multiple NVNO (enVVeno Medical)|Market Capitalization-to-Revenue Ratio SINT|Tenon Medical - P/S Multiple|Price to Sales ReWalk Robotics|autonomix.com (AMIX) - Price-to-Revenue Ratio|IVF - Price-to-Revenue Coefficient|Market Cap to Revenue BBLG|AXNX (axonics.com) - Market Cap to Sales Volume|Price-to-Revenue Ratio BIOLASE (BIOL)|DYNT (dynatronics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple FNA (Paragon 28)|P/S Multiple INVO Bioscience Inc. INVO